Download PDF
Synlett 2006(3): 0383-0386  
DOI: 10.1055/s-2006-926233
LETTER
© Georg Thieme Verlag Stuttgart · New York

A Versatile Synthesis of (±)-Deoxyfebrifugine, an Antimalarial Alkaloid Analogue, and Related Compounds

Joseph P. Michael*, Charles B. de Koning, Daniel P. Pienaar
Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, Johannesburg, PO Wits 2050, South Africa
Fax: +27(11)7176749; e-Mail: jmichael@aurum.wits.ac.za;
Further Information

Publication History

Received 25 November 2005
Publication Date:
06 February 2006 (online)

    Permissions and Reprints All articles of this category

Abstract

The title compound was prepared by a simple route involving Eschenmoser sulfide contraction between 3-(3-bromo-2-oxopropyl)quinazolin-4(3H)-one (11) and piperidine-2-thione (13) followed by chemoselective catalytic hydrogenation. This short but flexible procedure also permitted access to N-alkyl analogues, and to analogues in which the piperidine ring was replaced by other ­saturated nitrogen-containing heterocycles.

Key words

alkaloids - enaminones - heterocycles - piperidines - quinazolines

    References and Notes

  • 1a Jang CS. Fu FY. Wang CY. Huang KC. Lu G. Chou TC. Science  1946,  103:  59 
    Google Scholar
  • 1b Koepfli JB. Mead JF. Brockman JA. J. Am. Chem. Soc.  1947,  69:  1837 
    Google Scholar
  • 1c Kuehl FA. Spencer CF. Folkers K. J. Am. Chem. Soc.  1948,  70:  2091 
    Google Scholar
  • 1d Koepfli JB. Mead JF. Brockman JA. J. Am. Chem. Soc.  1949,  71:  1048 
    Google Scholar
  • 1e Koepfli JB. Brockman JA. Moffat J. J. Am. Chem. Soc.  1950,  72:  3323 
    Google Scholar
  • 2a Ablondi F. Gordon S. Morton J. Williams JH. J. Org. Chem.  1952,  17:  14 
    Google Scholar
  • 2b Hutchings EL. Gordon S. Ablondi F. Wolf CF. Williams JH. J. Org. Chem.  1952,  17:  19 
    Google Scholar
  • 2c Kato M. Inaba M. Itahana H. Ohara E. Nakamura K. Uesato S. Inouye H. Fujita T. Shoyakugaku Zasshi  1990,  44:  288 ; Chem. Abstr. 1991, 115, 64012f
    Google Scholar
  • 2d Khalil AT. Chang F.-R. Lee Y.-H. Chen C.-Y. Liaw C.-C. Ramesh P. Yuan S.-SF. Wu Y.-C. Arch. Pharm. Res.  2003,  26:  15 
    Google Scholar
  • 3 Takeuchi Y. Harayama T. Trends Heterocycl. Chem.  2001,  7:  65 
    Google Scholar
  • 4a Kobayashi S. Ueno M. Suzuki R. Ishitani H. Tetrahedron Lett.  1999,  40:  2175 
    CrossrefPubMedGoogle Scholar
  • 4b Kobayashi S. Ueno M. Suzuki R. Ishitani H. Kim H.-S. Wataya Y. J. Org. Chem.  1999,  64:  6833 
    CrossrefPubMedGoogle Scholar
  • 5a Murata K. Takano F. Fushiya S. Oshima Y. J. Nat. Prod.  1998,  61:  729 
    CrossrefGoogle Scholar
  • 5b Murata K. Takano F. Fushiya S. Oshima Y. Biochem. Pharm.  1999,  58:  1593 
    CrossrefGoogle Scholar
  • 6a Hirai S. Kikuchi H. Kim H.-S. Begum K. Wataya Y. Tasaka H. Miyazawa Y. Yamamoto K. Oshima Y. J. Med. Chem.  2003,  46:  4351 
    CrossrefGoogle Scholar
  • 6b Kikuchi H. Tasaka H. Hirai S. Takaya Y. Iwabuchi Y. Ooi H. Hatakeyama S. Kim H.-S. Wataya Y. Oshima Y. J. Med. Chem.  2002,  45:  2563 
    CrossrefGoogle Scholar
  • 6c Takeuchi Y. Koike M. Azuma K. Nishioka H. Abe H. Kim H.-S. Wataya Y. Harayama T. Chem. Pharm. Bull.  2001,  49:  721 
    CrossrefGoogle Scholar
  • 6d Takaya Y. Tasaka H. Chiba T. Uwai K. Tanitsu M. Kim H.-S. Wataya Y. Miura M. Takeshita M. Oshima Y. J. Med. Chem.  1999,  42:  3163 ; and references cited therein
    CrossrefGoogle Scholar
  • 7 Edeson JFB. Wilson T. Trans. R. Soc. Trop. Med. Hyg.  1955,  49:  543 
    CrossrefGoogle Scholar
  • For recent syntheses of optically active or racemic febrifugine, see the following:
  • 8a Takeuchi Y. Oshige M. Azuma K. Abe H. Harayama T. Chem. Pharm. Bull.  2005,  53:  868 
    CrossrefGoogle Scholar
  • 8b Ashoorzadeh A. Caprio V. Synlett  2005,  346 
    CrossrefGoogle Scholar
  • 8c Katoh M. Matsune R. Nagase H. Honda T. Tetrahedron Lett.  2004,  45:  6221 
    CrossrefGoogle Scholar
  • 8d Huang P.-Q. Wei B.-G. Ruan Y.-P. Synlett  2003,  1663 
    CrossrefGoogle Scholar
  • 8e Sugiura M. Hagio H. Hirabayashi R. Kobayashi S. Synlett  2001,  1225 
    CrossrefGoogle Scholar
  • 8f Ooi H. Urushibara A. Esumi T. Ibabuchi Y. Hatakeyama S. Org. Lett.  2001,  3:  953 
    CrossrefGoogle Scholar
  • 8g Sugiura M. Kobayashi S. Org. Lett.  2001,  3:  477 
    CrossrefGoogle Scholar
  • 8h Okitsu O. Suzuki R. Kobayashi S. J. Org. Chem.  2001,  66:  809 
    CrossrefGoogle Scholar
  • 8i Takeuchi Y. Azuma K. Takakura K. Abe H. Kim H.-S. Wataya Y. Harayama T. Tetrahedron  2001,  57:  1213 
    CrossrefGoogle Scholar
  • 8j

    For syntheses published prior to 2001, see the references cited in the preceding.
    CrossrefGoogle Scholar
  • 9a Jiang S. Zeng Q. Gettayacamin M. Tungtaeng A. Wannaying S. Lim A. Hansukjariya P. Okunji CO. Zhu S. Fang D. Antimicrob. Agents Chemother.  2005,  49:  1169 
    CrossrefGoogle Scholar
  • 9b Chien P.-L. Cheng CC. J. Med. Chem.  1970,  13:  867 
    CrossrefGoogle Scholar
  • 9c Fishman M. Cruickshank PA. J. Med. Chem.  1970,  13:  155 
    CrossrefGoogle Scholar
  • 9d Baker BR. Schaub RE. Joseph JP. McEvoy FJ. Williams JH. J. Org. Chem.  1953,  18:  133 ; and references cited therein
    CrossrefGoogle Scholar
  • 10 Takeuchi Y. Tokuda S. Takagi T. Koike M. Abe H. Harayama T. Shibata Y. Kim H.-S. Wataya Y. Heterocycles  1999,  51:  1869 
    CrossrefGoogle Scholar
  • 11 Review: Michael JP. de Koning CB. Gravestock D. Hosken GD. Howard AS. Jungmann CM. Krause RWM. Parsons AS. Pelly SC. Stanbury TV. Pure Appl. Chem.  1999,  71:  979 
    CrossrefGoogle Scholar
  • 12 Michael JP. de Koning CB. van der Westhuyzen CW. Org. Biomol. Chem.  2005,  3:  836 ; and references cited therein
    CrossrefGoogle Scholar
  • 13a Roth M. Dubs P. Götschi E. Eschenmoser A. Helv. Chim. Acta  1971,  54:  710 
    CrossrefGoogle Scholar
  • 13b Shiosaki K. In Comprehensive Organic Synthesis   Vol. 2:  Trost BM. Pergamon Press; Oxford: 1991.  p.865-892  
    CrossrefGoogle Scholar
  • 14 von Niementowski S. J. Prakt. Chem.  1895,  51:  564 
    Google Scholar
  • 15 Weygand F. Schmied-Kowarzik V. Chem. Ber.  1949,  82:  333 
    Google Scholar
  • 16 Brillon D. Synth. Commun.  1990,  20:  3085 
    CrossrefGoogle Scholar
  • 17 Honda T. Kimura M. Org. Lett.  2000,  2:  3925 
    CrossrefGoogle Scholar
  • 20a Baker BR. Querry MV. Schaub RE. Williams JH. J. Org. Chem.  1952,  17:  58 
    CrossrefGoogle Scholar
  • 20b For an alternative synthesis of (±)-deoxyfebrifugine from the same group, see: Baker BR. Querry MV. Kadish AF. Williams JH. J. Org. Chem.  1952,  17:  52 
    CrossrefGoogle Scholar
  • 21 Baker BR. Schaub RE. Querry MV. Williams JH. J. Org. Chem.  1952,  17:  97 
    CrossrefGoogle Scholar
  • 22 Ghirlando R. Howard AS. Katz RB. Michael JP. Tetrahedron  1984,  40:  2879 
    CrossrefGoogle Scholar
  • 24a Baker BR. Schaub RE. Williams JH. J. Org. Chem.  1952,  17:  109 
    CrossrefGoogle Scholar
  • 24b Baker BR. Schaub RE. Williams JH. J. Org. Chem.  1952,  17:  116 
    CrossrefGoogle Scholar
18

Synthesis of 3-[(3 Z )-2-Oxo-3-(piperidin-2-ylidene)propyl]quinazolin-4 (3 H )-one ( 15).
A mixture of 3-(3-bromo-2-oxopropyl)quinazolin-4 (3H)-one (11, 395 mg, 1.41 mmol) and piperidine-2-thione (13, 163 mg, 1.41 mmol) in dry THF (30 mL) was stirred at r.t. for 48 h until salt precipitation was complete. After evaporation of the solvent in vacuo, dry MeCN (25 mL), triphenylphosphine (PPh3, 0.92 g, 3.5 mmol) and 1-methylpiperidine (0.44 mL, 3.5 mmol) were sequentially added to the residue. Stirring was continued at r.t. for another 18 h. After evaporation of the solvent in vacuo, the residue was dissolved in CH2Cl2 (50 mL) and extracted with aq HCl (2 M, 3 × 20 mL). The combined aqueous extracts were washed with CH2Cl2 (10 mL), then made basic with concd aq NH3 solution. Extraction with CH2Cl2 (3 × 15 mL) was followed by washing of the combined organic extracts with brine (10 mL). Drying (Na2SO4), filtering and evaporation to dryness yielded crude product as a light brown solid, which was purified by column chromatography (EtOAc-hexane, 4:1) to afford 15 as a colourless solid (254 mg, 64%), mp 167.5-170 °C (from EtOAc-hexane) (lit. mp of the putative tautomer 16, [20] 167-170 °C; 176-178 °C after recrystallisation). MS: m/z calcd for C16H17N3O2: 283.1321; found: 283.1326 [M+]. IR (CHCl3): νmax = 2948, 2869, 1673 (s, quinazolinone C=O), 1607 (s, enaminone C=O), 1578, 1526, 1474 cm-1. 1H NMR (300 MHz, CDCl3): δ = 11.11 (1 H, br s, NH), 8.31 (1 H, d, J = 8.3 Hz, H-5), 8.04 (1 H, s, H-2), 7.71-7.78 (2 H, m, H-7 and H-8), 7.45-7.51 (1 H, m, H-6), 4.93 (1 H, s, NC=CH), 4.64 (2 H, s, O=CCH 2), 3.32 (2 H, dt, J = 5.7, 2.3 Hz, ring NCH 2), 2.39 (2 H, t, J = 6.2 Hz, NCCH 2), 1.67-1.81 (4 H, m, 2 × ring CH 2). 13C NMR: δ = 186.0 (enaminone C=O), 166.5 (NC=CH), 161.1 (quinazolinone C=O), 148.3, 147.2, 134.1, 127.4, 127.0, 126.8, 122.1, 90.2 (NC=CH), 52.4 (O=CCH2), 41.1 (ring NCH2), 28.5, 21.9, 18.9. MS (EI): m/z (%) = 283 (9) [M+], 255 (2), 220 (3), 124 (100), 82 (4), 55 (3).

19

Results of a more extensive crystallographic survey that includes 15 and representative examples of compounds 19 and 21 will be published elsewhere.

23

Synthesis of (±)-Deoxyfebrifugine ( 5).
Enaminone 15 (190 mg, 0.671 mmol) was dissolved in a mixture of MeOH (15 mL) and aq HCl (8.5 N, 0.20 mL). The solution was stirred over pre-hydrogenated PtO2·xH2O (Adams catalyst, 26 mg) under H2 gas (3 atm) for 6 h. After filtering through Celite®, the solvent was removed under reduced pressure and the residue was triturated with EtOH-MeOH (5:1), cooled down and left to precipitate overnight in the freezer. After filtering, the precipitate was identified as the dihydrochloride salt of (±)-deoxyfebrifugine, 5·2HCl (138 mg, 58%), mp 218-221 °C (decomp.) [lit. mp 228-230 °C (decomp.) [20] ]. 1H NMR (300 MHz, D2O): δ = 8.65 (1 H, s, H-2), 8.28 (1 H, d, J = 8.1 Hz, H-5), 8.04 (1 H, m, H-6), 7.74-7.83 (2 H, m, H-7 and H-8), 5.20 (2 H, s, O=CCH 2N), 3.70 (1 H, m, J = 7.1 Hz, NCH), 3.05-3.49 (4 H, m, ring NCH 2 and O=CCH 2CH), 1.92-2.11 (3 H, m, 1.5 × ring CH 2), 1.59-1.75 (3 H, m, 1.5 × ring CH 2). 13C NMR (50 MHz, D2O): δ = 204.4, 163.5, 151.7, 144.6, 139.2, 132.0, 129.4, 125.9, 122.5, 58.2, 54.7, 47.6, 45.1, 30.7, 24.3, 24.0. The salt was dissolved in sat. K2CO3 solution (5 mL), and the resulting solution was extracted with EtOAc (3 × 10 mL). The combined extracts were dried (MgSO4), filtered and evaporated in vacuo to give the free base as a cream-coloured solid which could be repeatedly recrystallised from EtOAc-hexane to afford (±)-deoxyfebrifugine (5) in quantitative yield from the hydrochloride salt; colourless needles, mp 127.5-129 °C (lit. [10] mp 139-141 °C; lit. [20] 138-140 °C). MS: m/z calcd for C16H20N3O2: 286.1556; found: 286.1559 [MH+]. IR (film) νmax = 3063 (w), 2930 (m), 2854 (w), 1729 (m), 1677 (s), 1613 (s), 1563 (w), 1474 (m) cm-1. 1H NMR (300 MHz, CDCl3): δ = 8.28 (1 H, d, J = 8.1 Hz, H-5), 7.89 (1 H, s, H-2), 7.72-7.80 (2 H, m, H-7 and H-8), 7.51 (1 H, dt, J = 7.3, 1.4 Hz, H-6), 4.84 (1 H, d, J = 17.4 Hz, O=CCH a HbN), 4.73 (1 H, d, J = 17.4 Hz, O=CCHa H b N), 3.04 (2 H, 2 × m, NCH and O=CCH a HbCH), 2.64-2.67 (3 H, m, ring NCH 2 and O=CCHa H b CH), 2.11 (1 H, br s, NH), 1.80 (1 H, br d, ring CH a Hb), ca. 1.64, 1.40, 1.23 (2 H, 2 H, 1 H, 3 × m, remaining ring CH 2). 13C NMR: δ = 202.1, 160.9, 148.2, 146.2, 134.5, 127.6, 127.4, 126.7, 121.8, 54.8, 52.7, 47.7, 46.7, 32.7, 26.0, 24.5. FAB-MS: m/z (%) = 286 (25) [MH+], 180 (5), 154 (100), 136 (74), 124 (9), 120 (13), 115 (5), 107 (26). The 1H NMR spectroscopic data agree with those reported in the literature. [10]